CareDx partners with 10x Genomics on transplant rejection research program

CareDx Inc. (NASDAQ: CDNA) announced a collaboration with 10x Genomics Inc. (NASDAQ: TXG) to establish ImmuneScape, a research initiative focused on studying transplant organ rejection and therapeutic response mechanisms.

The program will utilize 10x Genomics' Xenium spatial and Chromium Flex single cell platforms to examine antibody-mediated rejection and microvascular inflammation in transplant patients. The research aims to generate detailed maps of immune mechanisms underlying organ rejection to support future diagnostic development.

"This collaboration marks a meaningful step in advancing precision transplant care," said John Hanna, president and CEO of CareDx. "By uniting CareDx's clinical and diagnostic expertise with 10x Genomics' transcriptomics technologies, we're building upon a robust scientific foundation to drive future organ-health innovation across our diagnostic pipeline."

The initiative builds on CareDx's existing transplant biology research efforts, including the recent introduction of HistoMap Kidney, a tissue biopsy-based gene expression classifier for rejection subtyping. ImmuneScape will examine how tissue-level immune architecture correlates with clinical outcomes and response to treatments such as anti-CD38 therapies.

Serge Saxonov, co-founder and CEO of 10x Genomics, stated that examining immune activity at the single cell level "opens a new window into the cellular and molecular signatures of rejection that have historically been impossible to measure."

The platforms were selected for their ability to provide high-resolution profiling of immune biology across large cohorts and their throughput capacity for analyzing FFPE biopsy samples at scale, according to the companies' joint statement.

You May Also Be Interested In

• Takeda names Julie Kim as president and CEO after shareholder vote
• Natera's Signatera wins Japan approval for colorectal cancer
• Goldman Sachs Assumes Braze Inc (BRZE) at Buy